New China-based biotechs fueling growth in manufacturing across China
New guidelines will see poorer quality manufacturers drop out of the market.
A key trend to emerge at this year's CPHI & P-MEC China is the rise in the number of innovative China-based biotechs. This, coupled with the easing of regulatory pathways and an emerging CDMO sector, is fueling significant growth in manufacturing across China. In view of this, experts at the event will assess the Marketing Authorization Holder (MAH) Pilot Program, as well as recent reforms of China’s regulatory landscape and the opportunities for international pharma.
CPHI & P-MEC China – co-organized by UBM EMEA, CCCMHPIE, and UBM Sinoexpo – takes place at the Shanghai New International Expo Center (SNIEC) on 18-20 June 2019. The event will be co-located with ICSE, InnoPack, bioLIVE, NEX, Labworld, FDF, and EP & Clean Tech. Seen as the bellwether of pharmaceutical trends across the country, CPHI & P-MEC China’s agenda is packed with content from over 100 onsite conferences and activities as well as more than 50 seminars, with speakers from China and abroad.
With the Chinese pharma growing at a ferocious pace, CPHI & P-MEC China is expected to welcome 70,000 attendees in its 19th edition – a year-on-year increase of 55% – which is further indicative of the buoyancy of the Chinese market. The event is also expected to see a 6% increase in exhibitors, with more than 3,200 from over 120 countries in attendance.
“China is issuing new guidelines at a feverish pace and will be harmonized with ICH very quickly. The result is that over the next 2 to 3 years poorer quality manufacturers will drop out of the market and China’s manufacturers will look to compete in international markets as well as domestic,” CPHI Annual Report Expert, Bikash Chatterjee on outlook of 2019.
Wider market data also supports this ongoing boom, with China's pharmaceutical market projected to grow strongly from $115.2 billion in 2016 to $159.4 billion by 2021 and $234.2 billion by 2026. This represents a 10-year compound annual growth rate of 8.8% in local currency terms and 7.3% in US dollar terms. Similarly, bioprocessing in China has been on a trajectory of rapid growth, with a 39% growth in facilities, and total capacity is growing ≥8% annually, with biosimilars offering the largest growth potential.
At the 2019 edition, for the first time, CPHI & P-MEC China will launch bioLIVE – their new bioprocessing and manufacturing exhibition – which has evolved from the previous BioPh China and will run adjacent. This exposition is in response to the large molecule trend within the industry, and arrives at a particularly prominent moment. Within the last year, there has been a proliferation of biosimilars and double-digit approvals of biologics – as well as a host of investments taking place in contract services.
Marie Lagrenee, Brand Manager at CPHI & P-MEC China, commented: “The growth of the Chinese pharma economy has been exponential in recent years, with regulatory reforms spearheading the increased interest in the region from both domestic and international companies. With a bourgeoning CDMO sector and recent harmonization by ICH, it’s pivotal that events such as CPHI & P-MEC China provide a platform to drive growth, exchange new ideas and expedite new deals to help nurture this budding market.”
The third edition of China Pharma Week will take place alongside CPHI & P-MEC China, 17–21 June 2019 focusing on Leadership, Business, Networking, Innovation, Recognition and Knowledge. Activities will include plant visits, a networking dinner, women in leadership forum, summits and the Innovation Gallery Tours, giving a deeper work floor insight and dedicated industry conferences on different sectors.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance